Biotech stocks are shares in companies developing new medicines and treatments. They are among the market's most interesting and most risky: a positive trial result or an approval can send a price sharply higher, while a disappointment can halve it in a day. A large part of the value sits in drugs that have not been approved yet. Below, our model ranks every US-listed biotech stock by score and momentum, updated after each close.
A biotech company typically develops drugs from idea to approval — a process that takes many years and costs billions before a single dollar comes in. Some have made it all the way to steady earnings: Regeneron and Vertex sell approved medicines today. Others are still spending, such as Ascendis Pharma and Halozyme. The theme also holds service and tools companies like IQVIA and QIAGEN, which sell into the industry rather than run trials themselves — a much steadier business.
Trial results. A drug goes through three phases before approval. Phase 3 readouts are the single events that move prices most — often double-digit percentages in a day, in either direction.
Regulatory decisions. The FDA decides whether a product may be sold and on what terms. A delayed decision can hit the price almost as hard as a rejection.
The cash runway. A company without earnings has to fund development. If the money runs short, it may have to issue new shares, diluting existing owners. It is the most overlooked risk in the sector.
Takeovers. Large pharmaceutical companies buy biotech to fill their own pipelines, and rumours alone can lift a price.
They swing far more than most shares, so they tend to fit best as a smaller part of a spread portfolio. If you want exposure to medicine with lower risk, the large pharmaceutical companies are a steadier alternative — they have their own theme.
Biotech companies are typically smaller, developing new medicines and often not yet profitable. Pharma companies are large and established, with approved products and running earnings. Biotech therefore swings much more — and can rise much more on a single good result.
Because the quality score measures how soundly a company is run compared with every other stock. A company that does not sell anything yet has no figures to show it with. That is not a verdict on the science — it is a reminder that the value sits in expectations rather than earnings.
Three stages in testing a drug. Phase 1 tests safety in a small group, phase 2 tests whether it works, and phase 3 tests it in a large number of patients. Phase 3 is the most expensive and the most decisive — and typically where prices move most.